Browsing Workspace (UPSpace) by UP Author "Takuva, Simbarashe G."

Browsing Workspace (UPSpace) by UP Author "Takuva, Simbarashe G."

Sort by: Order: Results:

  • Allergic reactions to the Ad26.COV2.S vaccine in South Africa 
    Peter, Jonny; Day, Cascia; Takuva, Simbarashe G.; Takalani, Azwidihwi; Engelbrecht, Imke; Garrett, N.; Goga, Ameena Ebrahim; Louw, Vernon; Opie, Jessica; Jacobson, Barry; Sanne, Ian; Gail-Bekker, Linda; Gray, Glenda (Elsevier, 2022-02)
    BACKGROUND : The Janssen-Ad26.COV2.S vaccine is authorized for use in several countries, with more than 30 million doses administered. Mild and severe allergic adverse events following immunization (AEFI) have been ...
  • Incidence of cardiometabolic diseases in a Lesotho HIV cohort : evidence for policy decision-making 
    Sebilo, Motlalepula; Ledibane, Neo R.T.; Takuva, Simbarashe G. (AOSIS, 2021-06-28)
    BACKGROUND: Antiretroviral treatment (ART) has been associated with the development of certain cardiometabolic diseases (CMDs). The burden of CMDs amongst ART-experienced patients in sub-Saharan Africa was unknown. OBJECTIVE: ...
  • Safety evaluation of the single-dose Ad26. COV2.S vaccine among healthcare workers in the Sisonke study in South Africa : a phase 3b implementation trial 
    Takuva, Simbarashe G.; Takalani, Azwidhwi; Seocharan, shen; Yende-Zuma, Nonhlanhla; Reddy, Tarylee; Engelbrecht, Imke; Faesen, Mark; Khuto, Kentse; Whyte, Carmen J.; Bailey, Veronique; Trivella, Valentina; Peter, Jonathan; Opie, Jessica; Louw, Vernon; Rowji, Pradeep; Jacobson, Barry; Groenewald, Pamela; Dorrington, Rob E.; Laubscher, Ria; Bradshaw, Debbie; Moultrie, Harry; Fairall, Lara; Sanne, Ian; GailBekker, Linda; Gray, Glenda; Goga, Ameena Ebrahim; Garrett, Nigel (Public Library Science, 2022-06-21)
    Real-world evaluation of the safety profile of vaccines after licensure is crucial to accurately characterise safety beyond clinical trials, support continued use, and thereby improve public confidence. The Sisonke study ...
  • Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition 
    Corey, Lawrence; Gilbert, Peter B.; Juraska, Michal; Montefiori, David C.; Morris, Lynn; Karuna, Shelly T.; Edupuganti, Srilatha; Mgodi, Nyaradzo M.; DeCamp, Allan C.; Rudnicki, Erika; Huang, Yunda; Gonzales, Pedro; Cabello, Robinson; Orrell, Catherine; Lama, Javier R.; Laher, Fatima; Lazarus, Erica M.; Sanchez, Jorge; Frank, Ian; Hinojosa, Juan; Sobieszczyk, Magdalena E.; Marshall, Kyle E.; Mukwekwerere, Pamela G.; Makhema, Joseph; Baden, Lindsey R.; Mullins, James I.; Williamson, Carolyn; Hural, John; McElrath, Juliana; Bentley, Carter; Takuva, Simbarashe G.; Lorenzo, Margarita M. Gomez; Burns, David N.; Espy, Nicole; Randhawa, April K.; Kochar, Nidhi; Piwowar‑Manning, Estelle; Donnell, Deborah J.; Sista, Nirupama; Andrew, Philip; Kublin, James G.; Gray, Glenda; Ledgerwood, Julie E.; Mascola, John R.; Cohen, Myron S. (Massachusetts Medical Society, 2021-03-18)
    BACKGROUND : Whether a broadly neutralizing antibody (bnAb) can be used to prevent human immunodeficiency virus type 1 (HIV-1) acquisition is unclear. METHODS : We enrolled at-risk cisgender men and transgender persons in ...
  • Vaccine efficacy of ALVAC-HIV and bivalent subtype C gp120–MF59 in adults 
    Gray, Glenda E.; Bekker, Linda‑Gail; Laher, Fatima; Malahleha, Mookho; Allen, Mary; Moodie, Zoe; Grunenberg, Nicole; Huang, Yunda; Grove, Doug; Prigmore, Brittany; Kee, Jia J.; Benkeser, David; Hural, John; Innes, Craig; Lazarus, Erica; Meintjes, Graeme; Naicker, Nivashnee; Kalonji, Dishiki; Nchabeleng, Maphoshane; Sebe, Modulakgotla; Singh, Nishanta; Kotze, Philip; Kassim, Sheetal; Dubula, Thozama; Naicker, Vimla; Brumskine, William; Ncayiya, Cleon N.; Ward, Amy M.; Garrett, Nigel; Kistnasami, Girisha; Gaffoor, Zakir; Selepe, Pearl; Makhoba, Philisiwe B.; Mathebula, Matsontso P.; Mda, Pamela; Adonis, Tania; Mapetla, Katlego S.; Modibedi, Bontle; Philip, Tricia; Kobane, Gladys; Bentley, Carter; Ramirez, Shelly; Takuva, Simbarashe G.; Jones, Megan; Sikhosana, Mpho; Atujuna, Millicent; Andrasik, Michele; Hejazi, Nima S.; Puren, Adrian; Wiesner, Lubbe; Phogat, Sanjay; Granados, Carlos Diaz; Koutsoukos, Marguerite; Van Der Meeren, Olivier; Barnett, Susan W.; Kanesa‑Thasan, Niranjan; Kublin, James G.; McElrath, Juliana; Gilbert, Peter B.; Janes, Holly; Corey, Lawrence (Massachusetts Medical Society, 2021-03-25)
    BACKGROUND : A safe, effective vaccine is essential to eradicating human immunodeficiency virus (HIV) infection. A canarypox–protein HIV vaccine regimen (ALVAC-HIV plus AIDSVAX B/E) showed modest efficacy in reducing ...